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A healthy vaginal microbiota is considered to be significant for maintaining vaginal health 
and preventing infections. However, certain vaginal bacterial commensal species serve 
an important first line of defense of the body. Any disruption of this microbial barrier might 
result in a number of urogenital conditions including aerobic vaginitis (AV) and bacterial 
vaginosis (BV). The health of the vagina is closely associated with inhabitant microbi-
ota. Furthermore, these microbes maintain a low vaginal pH, prevent the acquisition of 
pathogens, stimulate or moderate the local innate immune system, and further protect 
against complications during pregnancies. Therefore, this review will focus on vaginal 
microbial “health” in the lower reproductive tract of women and on the physiological 
characteristics that determine the well-being of reproductive health. In addition, we 
explore the distinct versus shared characteristics of BV and AV, which are commonly 
associated with increased risk for preterm delivery.
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iNTRODUCTiON
Commensal microbiota associated with the human body influence many aspects of fetal develop-
ment, physiological function, immunity at mucosal surfaces, susceptibility to diseases and ability to 
assimilate nutrients (1). As such, commensals in the lower female reproductive tract are significant 
in maintaining vaginal health as well preventing infections (2).
Human vaginal infections are associated with significantly increased risk of preterm birth in 
women (3, 4). If untreated, they can lead to pelvic inflammatory diseases (PID), which can cause 
tubal infertility, ectopic pregnancy, reproductive dysfunction, and adverse pregnancy outcomes 
(including preterm delivery and low birth weight) (3, 4). Vaginal infections may contribute to the 
progression of cervical dysplasia, increased risk of post-delivery infections, HIV, and herpes simplex 
virus-2 (HSV-2) acquisition and transmission (3, 5, 6). However, the unexpected pregnancy outcome 
and premature birth due to aerobic vaginitis (AV) and bacterial vaginosis (BV) infections in prenatal 
health services among asymptomatic pregnant women is high in Africa and worldwide (7).
The contribution of AV and BV to vaginal health and pregnancy outcome has been investigated 
for over a century, yet they remain incompletely understood (8). For example, in epidemiologic 
studies, it has been suggested that having multiple sexual partners, increased maternal age, previous 
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spontaneous abortions, and altered vaginal bacterial communi-
ties (including decreased Lactobacillus species and concurrent 
colonization with Candida species) are the risk factors for vaginal 
colonization with microbes associated with endogenous infection 
such as AV and BV (8, 9). However, the unexpected pregnancy 
outcome and premature birth due to AV and BV infections in 
prenatal health services among asymptomatic pregnant women 
are high in Africa and worldwide (7).
THe HeALTHY vAGiNAL MiCROBiOMe
The vagina is a highly nutrient-rich chamber for microbes (10). 
As a result, the composition of the vaginal microbiota is affected 
by numerous host factors, including age, changes in hormone 
levels (during the menstrual cycle, during menopause, preg-
nancy, or as a result of hormone contraceptive use), other genital 
infections, as well as sexual and hygiene practices (1, 11). Most 
of these commensal microbiotas do exist in mutualistic relation-
ships with their human hosts, although a few are opportunistic 
pathogens that can cause chronic infections, preterm delivery, or 
life-threatening maternal and fetal diseases (1, 6).
MUTUALiSTiC HOST–COMMeNSAL 
ReLATiONSHiPS iN THe LOweR FeMALe 
RePRODUCTive TRACT
Several bacterial species colonize both the gastrointestinal 
and reproductive tracts of women, in addition, the rectum has 
been suggested to provide an essential source of organisms that 
commonly colonize the vagina (11). This is of significance since 
bacteria are repeatedly shed from the body in vaginal secre-
tions, and bacterial regrowth must happen to replenish their 
number (1).
Some of the required nutrients are derived from host epithelial 
dead cells, while others are derived from glandular secretions 
in the lower reproductive tract (1). The vaginal epithelium has a 
limited blood supply and depends on diffusion of glucose, oxy-
gen, and numerous vital nutrients from underlying submucosal 
tissues that result in the relatively anaerobic environment at the 
genital mucosa (12). In addition, the vaginal mucosa undergoes 
recurring cycles of proliferation of the basal layer, maturation, 
and desquamation into the vaginal lumen (12).
The vagina harbors a collection of microbes that are distinct 
from other human surfaces and mucosal sites, with a reduced 
microbial diversity dominated by Lactobacillus species, believed 
to cause acidification of this environment (13). Furthermore, the 
ability of lactobacilli to colonize the vaginal mucosa is influenced 
by the route of delivery and extent of adhesion to vaginal epithe-
lial cells (14).
PHYSiOLOGiCAL vAGiNAL DiSCHARGe 
AND THe MiCROBiOMe
Notable changes occur in the physiology, immunology and 
microbiology of the female reproductive tract following the onset 
of puberty. The lower reproductive tract before puberty appears 
red, due to many blood vessels under the thin hypo-estrogenic 
mucosa (15). Before puberty, the vaginal pH is close to neutral 
but not <0.4.7, and the microbiome is closely related to the 
predominant fecal bacterial species.
Healthy women of reproductive age typically have some 
degree of vaginal discharge, with the quantity and type of secre-
tion varying during the menstrual cycle as a result of hormonal 
fluctuations (15). Before ovulation, estrogen levels increase, alter-
ing cervical mucus from a thicker, sticky consistency to clearer, 
wetter, more elastic and slippery in preparation for fertilization 
(16). After ovulation, estrogen levels decline and progesterone 
levels increase, resulting in cervical mucus becoming thicker, 
sticky, and less permissive to sperm motility (17).
With the increase of the estrogen levels around puberty, the 
genital mucosa thickens, becoming a lighter pink in color and 
becomes colonized with Lactobacillus species which produce 
lactic acid and hydrogen peroxide (H2O2) to lower the pH below 
4.5 (18). Production of H2O2 by certain Lactobacillus species is 
thought to be essential in inhibiting the overgrowth of normal 
facultative anaerobes (15, 19).
Following puberty, adolescent genital secretions are produced 
by a number of glands, including the vulva, sebaceous and sweat, 
appearing white (15). In addition to mucus, other common 
constituents of these secretions include exfoliated epithelial 
cells, secretions from the upper reproductive tract, immune 
molecules, and metabolic by-products (15). This white discharge 
characteristically does not adhere to the vaginal walls, pools in 
the posterior fornix, and has an acidic pH of <4.5 (16). In adult 
women, normal variations in the menstrual cycle, hormonal con-
traception use, and different stressors may alter the consistency, 
color, and amount of vaginal discharge (18).
Due to increasing estrogen levels following puberty, sexually 
matured women have a lower reproductive tract that favors lacto-
bacilli colonization. Estrogen results in thicker stratified epithelia 
and higher glycogen concentrations with Lactobacillus species 
contributing to a lower pH to ≤4.5 in the vagina (10), due to lactic 
acid and H2O2 production. In addition to Lactobacillus species, 
some commensal microorganisms commonly identified in the 
lower reproductive tract include Candida albicans, Staphylococcus 
aureus, and Streptococcus agalactiae (group B Streptococcus) (20). 
These can cause changes in discharge if they are not controlled 
and become overgrown (20).
OTHeR COMMON CAUSeS OF 
ABNORMAL vAGiNAL DiSCHARGe
Abnormal vaginal discharge differs in color and consistency 
(thin, thick, frothy, yellow, green, gray, or white) compared with 
physiological (normal) discharge, and frequently is associated 
with other symptoms, including itching, fishy, and foul smelling 
(15). Abnormal discharge is typically caused by vaginal infec-
tions, although some relatively common non-infectious etiolo-
gies occur as well (21).
Infectious causes of abnormal discharge usually include 
sexually transmitted infections including Chlamydia trachomatis, 
Neisseria gonorrhoeae, Trichomonas vaginalis, Ureaplasma, and less 
TABLe 1 | Comparison of clinical and microbiological characteristics of aerobic 
vaginitis (AV) and bacterial vaginosis (BV).
Characteristics Av Bv
Clinical
pH >4.5, usually >6 ≥4.5
Discharge Yellowish White, homogenous
Epithelial inflammation Present None
Shed epithelial cells Parabasal cells Clue cells
Whiff test (fishy amine 
odor)
Negative Positive
Lactobacilli species Displaced Displaced
Microbiological Group B Streptococcus Gardnerella vaginalis
Common pathogens Enterococcus faecalis Atopobium vaginae
Escherichia coli BVAB2
Staphylococcus aureus Megasphaera species
Immunological
Inflammatory cytokines High Moderate
Immune reaction 
(cytokines)
Reactive None reactive
Treatment Kanamycin Metronidazole
Clindamycin topical Clindamycin
Fluoroquinolones
i.e., Ciprofloxacin and 
ofloxacin
TABLe 2 | Microscopic diagnosis criteria for aerobic vaginitis (AV) (27).
Av score # Lactobacillary grades Number of leukocytes Proportion of toxic 
leukocytes
Background flora Proportion of parabasal 
epitheliocytes
0 I and IIa 10/hpfa None or sporadic Unremarkable or cytolysis None or <1%
1 IIb >10/hpfa and ≤10/Epithelial cell 50% of Leukocytes Small coliform bacilli ≤10%
2 III 10/Epithelial cell 50% of Leukocytes Cocci or chains >10%
aHigh-power field (hpf) (400× magnification).
# Lactobacillary grade I consists of numerous pleomorphic lactobacilli and no other bacteria.
# Lactobacillary grade IIa consists of Lactobacillus species predominance but with some mixed microbiota: LBG IIb consists also of a mixed microbiota but the proportion of 
lactobacilli being severely decreased as a result of an increased number of the bacteria.
# Lactobacillary grade III consists of lactobacilli severely depressed or absent because of the overgrowth of other bacteria.
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commonly HSV-2 and endogenous infections (i.e. dysbiotic out-
growths of common commensal bacterial such as in AV and BV).
Non-infectious causes of vaginal discharge include vaginal 
douching, using perfumed soaps for cleaning, some laundry 
detergents, toilet paper, fabric softeners, and other feminine 
hygiene products that may act as irritants and cause abnormal 
discharge (22). Sometimes, foreign bodies (such as a retained 
tampon, condom, or toilet papers) may result in a malodorous or 
bloody discharge (22).
BACTeRiAL vAGiNOSiS
Bacterial vaginosis is defined according to the presence of clinical 
symptoms and increased vaginal pH, typically ≥4.5, existence 
of white adherent discharge that contains exfoliated epithelial 
cells with Gram-variable polymorphic rod-shaped bacteria 
attached to their surfaces (clue cells), and a fishy odor (23). 
BV is typically polymicrobial, characterized by the presence of 
mainly anaerobic microorganisms including Gardnerella vagi-
nalis, Prevotella species, and Mycoplasma hominis, Mobiluncus 
species (8, 24, 25). An increased risk of PID, STIs (in addition 
to HIV infection), and preterm delivery in pregnant women is 
associated with BV (13, 26).
AeROBiC vAGiNiTiS
Aerobic vaginitis was first characterized in 2002 (21), as a vaginal 
condition distinct from BV, which may require different clinical 
management and have distinct clinical risks (27). Like BV, AV is 
defined by disruption in Lactobacillus dominance but is accom-
panied by more extreme inflammatory changes than BV and the 
presence of mainly aerobic enteric commensals or pathogens, 
including Group B Streptococcus (S. agalactiae), Enterococcus 
faecalis, Escherichia coli, and S. aureus (20, 27–31). AV has been 
observed in 8–11% of pregnant women (27, 28) and in 5–24% of 
women reporting vaginal complaints (24, 27).
In certain cases, AV is associated with more genital inflamma-
tion, increased numbers of leukocytes visible in vaginal smears, 
with increased activity to pathogens [termed “toxic leukocytes” 
(32)]. Women with AV tend to have thinner vaginal mucosa 
than those with BV, with increased numbers of intermediate and 
parabasal cells in vaginal smears, indicative of increased turnover 
and desquamation of superficial epithelial cell layers (32). The 
comparison of clinical and microbiological characteristics of AV 
and BV is summarized in Table 1.
Both BV and AV diagnosis is based on wet mount microscopy, 
with diagnosis based on deficiency of Lactobacillus species (33). 
Unlike BV, AV wet mounts are positive for cocci or coarse bacilli, 
positive for parabasal epithelial cells, and positive for vaginal 
leukocytes (plus their granular aspect) (30). The diagnosis of AV 
is also based on molecular diagnostic methods and microscopic 
criteria graded on a quantitative scale (27, 30) (Table 2). Donders 
et  al. (27) have proposed an algorithm for grading AV that is 
similar to the Nugent scoring system, where the number of points 
establishes the composite AV score, with the maximum score 
being 10. Like the Nugent scoring system used for grading BV, the 
AV score may indicate normal, intermediate, or severe AV (27).
Lactobacillary grades are the basis for a composite score to 
which the following four variables have been added: (a) propor-
tional number of lactobacilli; (b) the presence of toxic leukocytes; 
(c) the presence of parabasal epithelial cells; and (d) the type of 
background microbiota (27).
Aerobic vaginitis, without an accurate diagnosis, might be 
incorrectly diagnosed as BV, leading to incorrect treatment or 
even more severe complications of AV such as desquamative 
inflammatory vaginitis, which is considered to increase the risk 
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of preterm delivery, chorioamnionitis, and funisitis of the fetus 
during pregnancy (7).
S. agalactiae iN Av
Streptococcus agalactiae (Group B Streptococcus) is a member of 
the commensal microbiota of the human intestinal and geni-
tourinary tracts and is also an important pathogen in AV and 
other human infections (34). Colonization with GBS is the major 
risk factor for early-onset invasive GBS disease in newborns 
(35, 36). GBS rarely cause infections in healthy adults; however, 
occasionally it may cause morbidity in the elderly, in pregnant 
women, and in patients with underlying predisposing conditions 
(34, 35).
Maternal colonization with GBS in pregnant women at deliv-
ery is associated with neonatal sepsis, meningitis, and pneumonia 
(7, 13). The composition of the vaginal microbiota is considered 
to be very different from that present at other human body 
sites (13). Currently, GBS is considered to be the leading cause 
of early-onset sepsis worldwide (37, 38). In addition, GBS and 
E. faecalis are associated with preterm birth, very low birth weight 
delivery, and puerperal sepsis, which cause substantial morbidity 
and mortality in sub-Saharan Africa (4, 37, 39).
Prevention of GBS infections in pregnant women and their 
infants through maternal immunization has been a vision for 
decades and now is an achievable goal (40). Although GBS can 
cause asymptomatic bacteriuria, lower urinary tract infection, and 
acute pyelonephritis, most pregnant women have asymptomatic 
bacteriuria (40–42). Intrauterine fetal death, chorioamnionitis, 
and early-onset neonatal disease all are increased among women 
with untreated GBS bacteriuria (40, 43).
TReATMeNT FOR Av AND Bv
There is no generally accepted clinical strategy for treating AV 
(44). AV is treated with antibiotics with intrinsic activity against 
bacteria of fecal origin, in addition to ensuring minimal interfer-
ence with vaginal Lactobacillus species (44). Antibiotics alone 
may not be adequate for most patients with AV due to the amount 
of inflammation typically associated with this condition, includ-
ing infiltrating leukocytes and parabasal cells (27).
For this reason, the appropriate diagnosis and distinction 
between AV and BV is very crucial as their treatment is different. 
Unlike BV, AV does not respond well to metronidazole, which 
is commonly used for the treatment of T. vaginalis and BV (33). 
Clindamycin is therefore considered to be a better choice than met-
ronidazole for pregnant women with an abnormal vaginal micro-
biota (45). Fluoroquinolones, such as ciprofloxacin and ofloxacin, 
have been used in treatment because they have little effect on the 
normal flora allowing for a rapid recovery from AV (45).
Han et  al. (44), proposed that best practice for treating AV 
would be to base it on microscopy findings with local treatment 
with any combination of antibiotics (for the infectious agent), 
topical steroids (to reduce inflammation), and estrogen (to treat 
atrophy). To accomplish a rapid as well as short-term improvement 
for severe symptoms, systemic therapy with moxifloxacin can be 
used, especially in infections with group B streptococci and for 
methicillin resistant S. aureus (4).
In sub-Saharan Africa countries, sophisticated microbiota 
detection and administration of clinical interventions are definitely 
impossible at the moment. Assistance in lowering the morbidity 
and mortality rate is needed and can only occur if scientists in 
developing countries use the latest molecular technologies as well 
genetic investigations to have better understanding of the causes 
of preterm labor, particularly the triggers produced directly by 
bacteria or via the host, that can lead to irreversible preterm reac-
tions (31). Furthermore, for diagnosis and interventional purpose, 
products to be applied to the developing world, as well remote and 
rural areas, must be simple, easy to use, and well understood.
Direct use of probiotics inserted into the vagina is worthy of 
consideration. However, retention of accessibility of the strains, 
which are available to the participants in need, appropriate stor-
age, and cost of such capsules, are challenges that will have to be 
overcome.
CONCLUSiON
Maintaining a healthy vaginal environment is considered a chal-
lenge worldwide. To prevent the risk of infection, health-care 
professionals should consider enhancing education to improve 
women’s knowledge of reproductive health and the distinction 
between AV and BV. We believe that the assessment of healthy 
vaginal microbiomes, in combination with host genetics, particu-
larly to AV and BV infections and preterm delivery, is urgently 
needed.
Considering the existing knowledge gap regarding AV, pri-
marily in Africa, there is a need to identify antibiotic sensitivity 
profiles of the aerobic and anaerobic vaginal pathogens in women 
of reproductive age to prevent adverse pregnancy outcomes 
due to opportunistic pathogens, many of which demonstrate 
antimicrobial resistance (46). The study of vaginal microbiomes 
will provide an opportunity to define vaginal health, and the 
link between vaginal infections and commensal opportunistic 
microbial pathogens in pregnant women. Such surveillance stud-
ies will contribute significantly to the literature by establishing 
epidemiological trends of AV and BV and may well inform about 
the importance of maternal reproductive health for positive 
pregnancy outcomes.
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